Total Payments
$9,651
2024 Payments
$1,909
Companies
48
Transactions
502
Medicare Patients
4,286
Medicare Billing
$1.0M
Payment Breakdown by Category
Food & Beverage$9,153 (94.8%)
Education$498.02 (5.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,153 | 491 | 94.8% |
| Education | $498.02 | 11 | 5.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $1,646 | 111 | $0 (2024) |
| Amgen Inc. | $1,218 | 53 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $735.38 | 38 | $0 (2024) |
| Merck Sharp & Dohme LLC | $696.33 | 41 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $542.34 | 32 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $535.45 | 32 | $0 (2024) |
| Lilly USA, LLC | $493.05 | 18 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $423.20 | 22 | $0 (2019) |
| Gilead Sciences, Inc. | $278.48 | 9 | $0 (2024) |
| Incyte Corporation | $259.29 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,909 | 85 | E.R. Squibb & Sons, L.L.C. ($200.18) |
| 2023 | $1,774 | 91 | Gilead Sciences, Inc. ($189.34) |
| 2022 | $395.47 | 21 | Merck Sharp & Dohme LLC ($64.99) |
| 2021 | $165.94 | 5 | Janssen Biotech, Inc. ($121.13) |
| 2020 | $651.89 | 26 | Lilly USA, LLC ($208.97) |
| 2019 | $1,792 | 99 | Genentech USA, Inc. ($552.41) |
| 2018 | $1,503 | 90 | Genentech USA, Inc. ($372.99) |
| 2017 | $1,460 | 85 | Genentech USA, Inc. ($437.16) |
All Payment Transactions
502 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $25.28 | General |
| Category: Oncology | ||||||
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $32.90 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $28.72 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $21.21 | General |
| Category: Hematology/Oncology | ||||||
| 10/25/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $26.45 | General |
| Category: Hematology/Oncology | ||||||
| 10/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: Oncology | ||||||
| 10/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $28.83 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $25.47 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $2.04 | General |
| Category: Oncology | ||||||
| 09/12/2024 | GlaxoSmithKline, LLC. | BEXSERO (Biological), PEDIARIX, ROTARIX | Food and Beverage | In-kind items and services | $14.14 | General |
| Category: VACCINES | ||||||
| 08/28/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $25.85 | General |
| Category: Oncology | ||||||
| 08/23/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $21.99 | General |
| Category: Hematology/Oncology | ||||||
| 08/22/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $28.37 | General |
| Category: Oncology | ||||||
| 08/12/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $22.73 | General |
| 08/08/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $14.32 | General |
| Category: ONCOLOGY | ||||||
| 08/05/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $23.63 | General |
| Category: Oncology | ||||||
| 08/05/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $20.31 | General |
| Category: Oncology | ||||||
| 08/01/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $32.84 | General |
| 07/30/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $20.87 | General |
| 07/29/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.42 | General |
| Category: ONCOLOGY | ||||||
| 07/22/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.19 | General |
| 07/22/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 07/19/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $26.69 | General |
| Category: Oncology | ||||||
| 07/17/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $32.07 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 1,295 | 2,814 | $769,454 | $260,016 |
| 2022 | 12 | 1,172 | 2,528 | $709,886 | $245,472 |
| 2021 | 11 | 947 | 2,423 | $695,505 | $274,423 |
| 2020 | 16 | 872 | 4,043 | $624,593 | $249,596 |
Total Patients
4,286
Total Services
11,808
Medicare Billing
$1.0M
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 187 | 704 | $171,300 | $67,169 | 39.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 307 | 678 | $193,354 | $61,180 | 31.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 145 | 608 | $97,056 | $40,126 | 41.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 170 | 187 | $88,642 | $25,482 | 28.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 93 | 188 | $71,628 | $24,095 | 33.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 126 | 135 | $45,006 | $13,696 | 30.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 92 | 92 | $39,120 | $9,448 | 24.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 93 | 140 | $28,133 | $8,517 | 30.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 51 | 51 | $27,642 | $7,868 | 28.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 31 | 31 | $7,572 | $2,436 | 32.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 207 | 686 | $161,590 | $56,943 | 35.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 211 | 450 | $126,660 | $42,092 | 33.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 36 | 203 | $71,050 | $37,812 | 53.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 170 | 189 | $92,628 | $28,676 | 31.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 86 | 223 | $84,963 | $26,440 | 31.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 159 | 271 | $51,924 | $16,641 | 32.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 69 | 268 | $42,976 | $15,505 | 36.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 66 | 70 | $22,790 | $7,139 | 31.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 55 | 55 | $23,541 | $6,040 | 25.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 55 | 55 | $14,020 | $3,883 | 27.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 30 | 30 | $16,260 | $3,821 | 23.5% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 28 | 28 | $1,484 | $480.20 | 32.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 91 | 544 | $207,264 | $73,342 | 35.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 227 | 767 | $154,716 | $65,353 | 42.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 54 | 276 | $91,410 | $52,479 | 57.4% |
About Dr. Kalid Adab, MD
Dr. Kalid Adab, MD is a Hematology & Oncology healthcare provider based in Milwaukee, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/25/2009. The National Provider Identifier (NPI) number assigned to this provider is 1346473345.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kalid Adab, MD has received a total of $9,651 in payments from pharmaceutical and medical device companies, with $1,909 received in 2024. These payments were reported across 502 transactions from 48 companies. The most common payment nature is "Food and Beverage" ($9,153).
As a Medicare-enrolled provider, Adab has provided services to 4,286 Medicare beneficiaries, totaling 11,808 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology, Medical Oncology
- Location Milwaukee, WI
- Active Since 08/25/2009
- Last Updated 03/12/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1346473345
Products in Payments
- Alecensa (Biological) $579.57
- OPDIVO (Biological) $527.83
- KEYTRUDA (Biological) $457.49
- XARELTO (Drug) $423.20
- Perjeta (Biological) $293.23
- VERZENIO (Drug) $284.69
- TECENTRIQ (Biological) $283.19
- Neulasta (Biological) $260.30
- JAKAFI (Drug) $259.29
- Nplate (Biological) $228.31
- KISQALI (Drug) $219.39
- Kyprolis (Biological) $211.28
- Avastin (Biological) $197.54
- Trodelvy (Drug) $188.92
- ERLEADA (Drug) $182.03
- IMFINZI (Drug) $175.39
- CYRAMZA (Drug) $167.51
- Doptelet (Drug) $160.05
- Enhertu (Drug) $159.32
- GAZYVA (Biological) $151.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Milwaukee
Dr. Parameswaran Hari, Md, MD
Hematology & Oncology — Payments: $1.9M
Hematology & Oncology $1.9M
Dr. Lynn Malec, Md, MD
Hematology & Oncology — Payments: $597,741
Hematology & Oncology $597,741
Dr. Ehab Atallah, Md, MD
Hematology & Oncology — Payments: $481,534
Hematology & Oncology $481,534
Dr. Sayed Mehdi Hamadani, M.d, M.D
Hematology & Oncology — Payments: $452,049
Hematology & Oncology $452,049
Dr. Deepak Kilari, M.d, M.D
Hematology & Oncology — Payments: $351,939
Hematology & Oncology $351,939
Razelle Kurzrock, M.d, M.D
Hematology & Oncology — Payments: $252,132
Hematology & Oncology $252,132